Terms: = Ovarian cancer AND CIC, ENSG00000079432, 23152, Q96RK0, KIAA0306
20 results:
1. A putative role for ALDH inhibitors and chemoprevention of BRCA-mutation-driven tumors.
McGonigal S; Wu R; Grimley E; Turk EG; Zhai Y; Cho KR; Buckanovich RJ
Gynecol Oncol; 2023 Sep; 176():139-146. PubMed ID: 37535994
[TBL] [Abstract] [Full Text] [Related]
2. An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.
Chen YA; Lu CY; Cheng WF; Kuo KT; Yu CW; Ho HN; Chen HF; Pan SH
BMC Cancer; 2022 Sep; 22(1):967. PubMed ID: 36085021
[TBL] [Abstract] [Full Text] [Related]
3. Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System.
Park KJ; Broach V; Chi DS; Linkov I; Stanczyk FZ; Patel P; Jotwani A; Pearce CL; Pike MC; Kauff ND
Cancer Epidemiol Biomarkers Prev; 2022 Sep; 31(9):1823-1829. PubMed ID: 35700017
[TBL] [Abstract] [Full Text] [Related]
4. MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the cic transcriptional repressor.
Zhou Y; Wang M; Shuang T; Liu Y; Zhang Y; Shi C
Pathol Res Pract; 2019 Oct; 215(10):152606. PubMed ID: 31500928
[TBL] [Abstract] [Full Text] [Related]
5.
Kasten BB; Gangrade A; Kim H; Fan J; Ferrone S; Ferrone CR; Zinn KR; Buchsbaum DJ
Nucl Med Biol; 2018 Mar; 58():67-73. PubMed ID: 29413459
[TBL] [Abstract] [Full Text] [Related]
6. Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy.
Park KJ; Patel P; Linkov I; Jotwani A; Kauff N; Pike MC
Histopathology; 2018 Apr; 72(5):766-776. PubMed ID: 29197096
[TBL] [Abstract] [Full Text] [Related]
7. Phosphorylation of HSF1 at serine 326 residue is related to the maintenance of gynecologic cancer stem cells through expression of HSP27.
Yasuda K; Hirohashi Y; Mariya T; Murai A; Tabuchi Y; Kuroda T; Kusumoto H; Takaya A; Yamamoto E; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Tamura Y; Hirano H; Hasegawa T; Saito T; Sato N; Torigoe T
Oncotarget; 2017 May; 8(19):31540-31553. PubMed ID: 28415561
[TBL] [Abstract] [Full Text] [Related]
8. B7-H3-targeted
Kasten BB; Arend RC; Katre AA; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
Nucl Med Biol; 2017 Apr; 47():23-30. PubMed ID: 28104527
[TBL] [Abstract] [Full Text] [Related]
9. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
[TBL] [Abstract] [Full Text] [Related]
10. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract] [Full Text] [Related]
11. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
[TBL] [Abstract] [Full Text] [Related]
12. SLC25A1, or cic, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract] [Full Text] [Related]
13. cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract] [Full Text] [Related]
14. Isolation and characterization of stem-like cells from a human ovarian cancer cell line.
Wang L; Mezencev R; Bowen NJ; Matyunina LV; McDonald JF
Mol Cell Biochem; 2012 Apr; 363(1-2):257-68. PubMed ID: 22160925
[TBL] [Abstract] [Full Text] [Related]
15. Expression of aldehyde dehydrogenase 1 (ALDH1) in endometrioid adenocarcinoma and its clinical implications.
Rahadiani N; Ikeda J; Mamat S; Matsuzaki S; Ueda Y; Umehara R; Tian T; Wang Y; Enomoto T; Kimura T; Aozasa K; Morii E
Cancer Sci; 2011 Apr; 102(4):903-8. PubMed ID: 21231983
[TBL] [Abstract] [Full Text] [Related]
16. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations.
Cramer DW; O'Rourke DJ; Vitonis AF; Matulonis UA; Dijohnson DA; Sluss PM; Crum CP; Liu BC
Clin Chem; 2010 Dec; 56(12):1889-92. PubMed ID: 20943848
[TBL] [Abstract] [Full Text] [Related]
17. A sequential study of humoral factors in ovarian neoplasms.
Gupta SC; Agarwal J; Singh PA; Mehdiratta NK; Keswani NK
Indian J Pathol Microbiol; 1994 Jul; 37(3):319-26. PubMed ID: 7814065
[TBL] [Abstract] [Full Text] [Related]
18. Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.
Dobryszycka W; Gerber J; Zuwała-Jagiełło J; Ujec M
Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):41-50. PubMed ID: 1725104
[TBL] [Abstract] [Full Text] [Related]
19. Circulating IgG-specific immune complexes as a potential tumor marker in gynecological malignancies.
Dodd JK; Hicks LJ; Tyler JP; Crandon AJ; Hudson CN
Gynecol Oncol; 1983 Oct; 16(2):232-9. PubMed ID: 6629124
[TBL] [Abstract] [Full Text] [Related]
20. Levels of circulating immune complexes in patients with ovarian cancer.
Clarke AG; Vasey DP; Symonds EM; Faratian B; McLaughlin PJ; Price MR; Baldwin RW
Br J Obstet Gynaecol; 1982 Mar; 89(3):231-7. PubMed ID: 7066260
[TBL] [Abstract] [Full Text] [Related]
